+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Liver Cancer Diagnostics Market by Disease Stage, End User, Test Type, Technology - Global Forecast to 2030- Product Image
Liver Cancer Diagnostics Market by Disease Stage, End User, Test Type, Technology - Global Forecast to 2030- Product Image
Sale

Liver Cancer Diagnostics Market by Disease Stage, End User, Test Type, Technology - Global Forecast to 2030

  • PDF Icon

    Report

  • 186 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5716289
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior stakeholders in healthcare and diagnostics are facing a pivotal juncture as the liver cancer diagnostics market evolves amid rapid scientific progress and shifting policy frameworks. With the sector experiencing heightened complexity due to technological integration, early detection requirements, and regulatory flux, understanding these developments is crucial for confident, future-focused decision-making.

Market Snapshot: Liver Cancer Diagnostics Market Size & Growth

The liver cancer diagnostics market grew from USD 10.05 billion in 2024 to USD 10.73 billion in 2025 and is projected to reach USD 14.75 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.59%. These advancements reflect continued investments in precision diagnostics and the development of novel detection technologies designed to support early intervention and improved prognosis.

Scope & Segmentation: Analytical Coverage and Regional Dynamics

This report provides a comprehensive breakdown of the liver cancer diagnostics market, focusing on multiple operational and technological dimensions.

  • Disease Stage: Strategies and technologies span early-stage and advanced-stage liver cancer diagnostics, each presenting distinct requirements for detection and treatment guidance.
  • End Users: Ambulatory care centers, diagnostic centers, hospitals, and research laboratories form the core user base, each contributing unique diagnostic priorities and adoption practices.
  • Test Type:
    • Biomarkers: Genetic (ctDNA tests, MicroRNA tests) and protein markers (AFP, DCP)
    • Biopsy: Core needle biopsy, fine needle aspiration
    • Genetic Testing: Next-generation sequencing, PCR analysis
    • Imaging: CT, MRI, PET, ultrasound
  • Technology Focus: Application of modalities such as CT, MRI, PET, and ultrasound underpin the diagnostic workflows and integration with laboratory systems.
  • Regional Coverage: Americas—including the United States, Canada, Mexico, Brazil, and Argentina; Europe, Middle East & Africa—including the United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland; Asia-Pacific—including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, and Taiwan.
  • Key Companies: F. Hoffmann-La Roche Ltd., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Thermo Fisher Scientific Inc., bioMérieux SA, Hologic, Inc., QIAGEN N.V., Sysmex Corporation, Illumina, Inc.

Key Takeaways: Strategic Insights for Senior Decision-Makers

  • Precision medicine and innovative biomarker panels are reshaping early liver cancer detection, enabling clinicians to tailor treatments to patient-specific tumor biology.
  • Integration of artificial intelligence and machine learning is enhancing imaging analysis, improving lesion characterization and supporting timely, accurate clinical decisions.
  • Minimally invasive biopsy advances and liquid biopsy kits are facilitating patient-centric approaches that maximize analytical yield while reducing procedural risks.
  • Collaborative relationships between diagnostic firms and academic institutions are accelerating the validation and deployment of novel genetic and protein markers.
  • Regional variations highlight the importance of market-specific strategies that adapt to different infrastructure readiness, regulatory environments, and reimbursement frameworks.
  • Operational agility—through localized manufacturing, modular diagnostic platforms, and adaptive commercialization models—is becoming a critical driver of competitive advantage.

Tariff Impact: Navigating 2025 US Policy Adjustments

Revised United States tariffs implemented in 2025 on medical equipment and diagnostic reagents have led to increased capital and operational costs for key stakeholders. Diagnostic developers and healthcare facilities face new supply chain pressures, prompting reviews of sourcing strategies, consideration of domestic manufacturing partnerships, and engagement with alternative suppliers to protect margins and maintain reliable access to advanced diagnostic components.

Liver Cancer Diagnostics Market: Methodology & Data Sources

Market insights are derived from a rigorous blend of primary interviews with clinicians, laboratory leaders, and technology vendors, and secondary analysis of peer-reviewed literature, regulatory filings, and industry white papers. This approach ensures robust validation of trends and triangulation of findings to maintain analytical rigor.

Why This Report Matters

  • Decision-makers gain actionable intelligence to benchmark innovation, align investment decisions with evolving segment demands, and anticipate regulatory shifts in the liver cancer diagnostics market.
  • Stakeholders receive clarity on regional and segment-specific dynamics, enabling the creation of informed, tailored go-to-market and commercialization strategies.

Conclusion

The ongoing evolution within the liver cancer diagnostics sector demands adaptive, data-driven strategies. Senior leaders can leverage these insights to optimize operational efficiency, support innovation, and ensure equitable patient access to advanced diagnostics.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Liver Cancer Diagnostics Market, by Disease Stage
8.1. Introduction
8.2. Advanced Stage
8.3. Early Stage
9. Liver Cancer Diagnostics Market, by End User
9.1. Introduction
9.2. Ambulatory Care
9.3. Diagnostic Centers
9.4. Hospitals
9.5. Research Laboratories
10. Liver Cancer Diagnostics Market, by Test Type
10.1. Introduction
10.2. Biomarkers
10.2.1. Genetic Markers
10.2.1.1. ctDNA Tests
10.2.1.2. MicroRNA Tests
10.2.2. Protein Markers
10.2.2.1. AFP Tests
10.2.2.2. DCP Tests
10.3. Biopsy
10.3.1. Core Needle Biopsy
10.3.2. Fine Needle Aspiration
10.4. Genetic Testing
10.4.1. Next-Generation Sequencing
10.4.2. PCR Analysis
10.5. Imaging
10.5.1. CT
10.5.2. MRI
10.5.3. PET
10.5.4. Ultrasound
11. Liver Cancer Diagnostics Market, by Technology
11.1. Introduction
11.2. CT
11.3. MRI
11.4. PET
11.5. Ultrasound
12. Americas Liver Cancer Diagnostics Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Liver Cancer Diagnostics Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Liver Cancer Diagnostics Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. F. Hoffmann-La Roche Ltd.
15.3.2. Abbott Laboratories
15.3.3. Danaher Corporation
15.3.4. Siemens Healthineers AG
15.3.5. Thermo Fisher Scientific Inc.
15.3.6. bioMérieux SA
15.3.7. Hologic, Inc.
15.3.8. QIAGEN N.V.
15.3.9. Sysmex Corporation
15.3.10. Illumina, Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. LIVER CANCER DIAGNOSTICS MARKET MULTI-CURRENCY
FIGURE 2. LIVER CANCER DIAGNOSTICS MARKET MULTI-LANGUAGE
FIGURE 3. LIVER CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. LIVER CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. LIVER CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. LIVER CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CTDNA TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MICRORNA TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AFP TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DCP TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PCR ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CT, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CT, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 66. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 67. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 69. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 70. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 71. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 72. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 73. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 74. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 75. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 76. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 77. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 79. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 80. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 81. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 83. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 84. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 85. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 127. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 128. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 130. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 131. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 132. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 133. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 134. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 135. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 136. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 137. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 138. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 140. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 141. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 142. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 143. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 144. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 145. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 146. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 147. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 148. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 157. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 158. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 160. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 161. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 162. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 163. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 164. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 165. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 166. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 167. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 168. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 170. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 171. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 172. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 173. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 174. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 175. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 176. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 177. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 187. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 188. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 197. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 207. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 208. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 210. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 211. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 212. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 213. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 214. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 215. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 216. DENMARK LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 217. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 218. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 227. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 228. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 230. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 231. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 232. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 233. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 234. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 235. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 236. QATAR LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 237. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 238. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 240. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 241. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 242. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 243. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 244. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 245. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 246. FINLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 247. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 257. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 258. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 260. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 267. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 268. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 270. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 271. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 272. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 273. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 274. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 275. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 276. EGYPT LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 277. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 278. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 280. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 281. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 282. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 283. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 284. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 285. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 286. TURKEY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 287. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 288. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 289. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 290. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 291. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 296. ISRAEL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 297. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 298. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 300. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 301. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 302. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 303. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 304. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 305. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 306. NORWAY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 307. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 308. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 309. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 310. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 311. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 312. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 313. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 314. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 315. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 316. POLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 317. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 318. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 319. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 320. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 321. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 322. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 323. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 324. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 325. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 326. SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 327. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 328. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 329. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 330. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 331. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 332. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Liver Cancer Diagnostics market report include:
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Danaher Corporation
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • bioMérieux SA
  • Hologic, Inc.
  • QIAGEN N.V.
  • Sysmex Corporation
  • Illumina, Inc.

Table Information

Report AttributeDetails
No. of Pages186
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 10.73 Billion
Forecasted Market Value ( USD ) by 2030 $ 14.75 Billion
Compound Annual Growth Rate6.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report by Test Type (Laboratory Tests, Imaging, Endoscopy, Biopsy), End-use (Hospitals & Diagnostic Laboratories, Pharmaceutical & CRO Laboratories), and Region with Growth Forecasts, 2025-2030 - Product Image

Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report by Test Type (Laboratory Tests, Imaging, Endoscopy, Biopsy), End-use (Hospitals & Diagnostic Laboratories, Pharmaceutical & CRO Laboratories), and Region with Growth Forecasts, 2025-2030

  • Report
  • 150 Pages
  • Global
From
Liver Cancer Diagnostics - Global Strategic Business Report - Product Image

Liver Cancer Diagnostics - Global Strategic Business Report

  • Report
  • 88 Pages
  • Global
From
Liver Cancer Diagnostics Market Report 2025 - Product Image

Liver Cancer Diagnostics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Liver Cancer Diagnostic Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Liver Cancer Diagnostic Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Cancer Diagnostics Market by Diagnostic Type, Application, Regional Outlook - Global Forecast up to 2030 - Product Image

Cancer Diagnostics Market by Diagnostic Type, Application, Regional Outlook - Global Forecast up to 2030

  • Report
  • 120 Pages
  • Global
From

About the Liver Cancer Diagnostics Market

The Liver Cancer Diagnostics market is a subset of the larger Diagnostics industry. It is focused on the development and commercialization of tests and technologies used to detect and diagnose liver cancer. These tests can include imaging techniques such as ultrasound, computed tomography (CT) scans, and magnetic resonance imaging (MRI). Additionally, blood tests, biopsies, and other laboratory tests may be used to diagnose liver cancer. The Liver Cancer Diagnostics market is highly competitive, with a range of companies offering products and services. These include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Becton Dickinson, and Hologic. Other companies in the market include Agilent Technologies, Bio-Rad Laboratories, and Cepheid. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.